Literature DB >> 20926546

Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients.

A Ruzzo1, E Canestrari2, N Galluccio2, D Santini3, B Vincenzi3, G Tonini3, M Magnani2, F Graziano4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20926546     DOI： 10.1093/annonc/mdq472

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.

Authors:  Bríd M Ryan; Ana I Robles; Curtis C Harris
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

2.  Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.

Authors:  Janne B Kjersem; Tone Ikdahl; Tormod Guren; Eva Skovlund; Halfdan Sorbye; Julian Hamfjord; Per Pfeiffer; Bengt Glimelius; Christian Kersten; Hiroko Solvang; Kjell M Tveit; Elin H Kure
Journal:  BMC Cancer       Date:  2012-11-20       Impact factor: 4.430

Review 3.  Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.

Authors:  Scott M Langevin; Brock C Christensen
Journal:  Cancer Med       Date:  2014-06-02       Impact factor: 4.452

4.  Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.

Authors:  M Elise R Graham; Robert D Hart; Susan Douglas; Fawaz M Makki; Devanand Pinto; Angela L Butler; Martin Bullock; Matthew H Rigby; Jonathan R B Trites; S Mark Taylor; Rama Singh
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.